Literature DB >> 16364689

Screening and the prevention of gynecologic cancer: endometrial cancer.

Yukio Sonoda1, Richard R Barakat.   

Abstract

Over the years, endometrial cancer has remained the most common gynecologic malignancy in the United States. Two categories of endometrial cancer exist: type I and type II. Type I cancers constitute the majority of cases of endometrial cancer, and the risk factors for this type have been studied in greatest detail. These cancers are driven by estrogen, and many of the risk factors are directly or indirectly linked to a state of excessive estrogen. Protective factors seem to be related to conditions that may result in decreased estrogen exposure. Cure rates for endometrial cancer remain high, mainly because of the early stage at which the majority of cases present. Warning signs of abnormal vaginal bleeding or discharge allow detection of these cancers in their early stages. Screening for these cancers is not effective and often leads to additional unnecessary tests; thus, it is not currently recommended in the general population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364689     DOI: 10.1016/j.bpobgyn.2005.10.015

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  17 in total

1.  Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.

Authors:  Ashley Sinclair Felix; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Joel L Weissfeld; Faina Linkov
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

2.  Ethnic and geographic variations in corpus uteri cancer burden: evidence based on data from 29 states and the District of Columbia. CI5 IX, X and SEER data (1998-2010).

Authors:  Dominique Sighoko
Journal:  Cancer Causes Control       Date:  2014-07-03       Impact factor: 2.506

3.  Rationale and design of REWARD (revving-up exercise for sustained weight loss by altering neurological reward and drive): a randomized trial in obese endometrial cancer survivors.

Authors:  Nora L Nock; Anastasia Dimitropoulos; Stephen M Rao; Chris A Flask; Mark Schluchter; Kristine M Zanotti; Peter G Rose; John P Kirwan; Jay Alberts
Journal:  Contemp Clin Trials       Date:  2014-08-17       Impact factor: 2.226

4.  Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells.

Authors:  Xin Li; Xiaoping Qi; Lingyin Zhou; Deborah Catera; Neal S Rote; Judith Potashkin; Fadi W Abdul-Karim; George I Gorodeski
Journal:  Gynecol Oncol       Date:  2007-05-04       Impact factor: 5.482

5.  Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.

Authors:  Zoya Yurkovetsky; Shlomo Ta'asan; Steve Skates; Alex Rand; Aleksey Lomakin; Faina Linkov; Adele Marrangoni; Lyudmila Velikokhatnaya; Matthew Winans; Elieser Gorelik; G Larry Maxwell; Karen Lu; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2007-07-19       Impact factor: 5.482

6.  Cancer Progress and Priorities: Uterine Cancer.

Authors:  Ashley S Felix; Louise A Brinton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09       Impact factor: 4.254

7.  Long-term survival of endometrioid endometrial cancer patients.

Authors:  Leszek Gottwald; Piotr Pluta; Janusz Piekarski; Michał Spych; Katarzyna Hendzel; Katarzyna Topczewska-Tylinska; Dariusz Nejc; Robert Bibik; Jerzy Korczyński; Aleksandra Ciałkowska-Rysz
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

8.  The role of laparoscopy in the surgical treatment of endometrial cancer.

Authors:  Paweł S Pawłowicz; Urszula Ajdacka
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2015-02-17       Impact factor: 1.195

Review 9.  The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases.

Authors:  Tea Lanišnik Rižner
Journal:  Front Pharmacol       Date:  2016-02-18       Impact factor: 5.810

Review 10.  Hormone replacement therapy for women previously treated for endometrial cancer.

Authors:  Katharine A Edey; Stuart Rundle; Martha Hickey
Journal:  Cochrane Database Syst Rev       Date:  2018-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.